Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis

被引:160
作者
Vallbracht, I
Rieber, J
Oppermann, M
Förger, F
Siebert, U
Helmke, K
机构
[1] Univ Munich, Teaching Hosp, Krankenhaus Munchen Bogenhausen, D-81925 Munich, Germany
[2] Univ Munich, Med Klin Munchen, D-80539 Munich, Germany
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
关键词
D O I
10.1136/ard.2003.019877
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the additional diagnostic and clinical value of the second test generation of anti-cyclic citrullinated peptide antibodies (CCP2) compared with rheumatoid factor isotypes (IgG-RF, IgA-RF, IgM-RF) in patients with rheumatoid arthritis. Methods: This was a prospective study on 715 patients: rheumatoid arthritis (n=295), degenerative or other inflammatory joint disease (n=163), connective tissue disease or vasculitis (n=103), and healthy controls (n=154). Sera from each subject were tested for CCP2 and RF isotypes by enzyme linked immunosorbent assay (ELISA). Agreement with clinical indices such as disease activity, joint destruction, disease duration, and other laboratory tests was assessed. Sensitivity and specificity of the tests were evaluated taking the clinical diagnosis as the gold standard. Results: Highest sensitivity was found for IgM-RF (66.4%) and CCP (64.4%). Highest specificity was achieved by CCP (97.1%) and IgG-RF (91.0%). In rheumatoid patients with high disease activity or severe joint damage, CCP was more often present (81.4% and 83.6%) than all RF isotypes. Of special diagnostic value was the detection of positive CCP in 34.5% of all patients with rheumatoid arthritis when all measured RF isotypes (IgG-RF, IgA-RF, and IgM-RF) were negative. Conclusions: As a screening method for rheumatoid arthritis the IgM-RF and the CCP assays are superior to other RF isotypes. Positivity in the highly specific CCP ELISA supports the diagnosis of rheumatoid arthritis. CCP proved to be a powerful diagnostic tool, especially in ambiguous cases or RF negative patients with rheumatoid arthritis.
引用
收藏
页码:1079 / 1084
页数:6
相关论文
共 43 条
[1]  
Anderson JJ, 2000, ARTHRITIS RHEUM, V43, P22, DOI 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO
[2]  
2-9
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]   Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis [J].
Bas, S ;
Genevay, S ;
Meyer, O ;
Gabay, C .
RHEUMATOLOGY, 2003, 42 (05) :677-680
[5]   Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].
Boers, M ;
Verhoeven, AC ;
Markusse, HM ;
vandeLaar, MAFJ ;
Westhovens, R ;
vanDenderen, JC ;
vanZeben, D ;
Dijkmans, BAC ;
Peeters, AJ ;
Jacobs, P ;
vandenBrink, HR ;
Schouten, HJA ;
vanderHeijde, DMFM ;
Boonen, A ;
vanderLinden, S .
LANCET, 1997, 350 (9074) :309-318
[6]   DISEASE-ACTIVITY AND JOINT DAMAGE PROGRESSION IN EARLY RHEUMATOID-ARTHRITIS - RELATION TO IGG, IGA, AND IGM RHEUMATOID-FACTOR [J].
EBERHARDT, KB ;
TRUEDSSON, L ;
PETTERSSON, H ;
SVENSSON, B ;
STIGSSON, L ;
EBERHARDT, JL ;
WOLLHEIM, FA .
ANNALS OF THE RHEUMATIC DISEASES, 1990, 49 (11) :906-909
[7]  
EGGELAND T, 1983, CLIN RHEUM DIS, V9, P135
[8]  
EGSMOSE C, 1995, J RHEUMATOL, V22, P2208
[9]   ASSESSING DISABILITY IN PATIENTS WITH RHEUMATOID-ARTHRITIS - USE OF A SWEDISH VERSION OF THE STANFORD HEALTH ASSESSMENT QUESTIONNAIRE [J].
EKDAHL, C ;
EBERHARDT, K ;
ANDERSSON, SI ;
SVENSSON, B .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1988, 17 (04) :263-271
[10]   THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740